Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Photodermatol Photoimmunol Photomed ; 23(6): 229-33, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17986058

RESUMO

BACKGROUND: In recent years, narrow-band ultraviolet B (NB-UVB, 311-313 nm) has been found to be beneficial for early-stages mycosis fungoides (MF). The aim of this study is to investigate the effect of NB-UVB in 20 patients with early-stage MF. METHODS: Twenty patients (10 women and 10 men, mean age 54 +/- 22 years) with clinically and histologically confirmed MF were enrolled in the study. All of the patients had clinical stage I disease (T1 or T2, N0, M0) with cutaneous involvement, consisting of patch-stage disease of limited extent, in 50% of the cases (stage IA), and more widespread in the other 50% (stage IB). All the patients were treated with NB-UVB therapy until more than 95% clearance of the patient's skin lesions had occurred. RESULTS: A complete response was achieved in 90% of the cases after a mean of 29 +/- 14 treatments within a mean period of 4 months (range 1-8 months), with an average cumulative dose of 25 +/- 16.77 J/cm(2). In the follow-up period, relapse occurred after a mean period of 8 months (range 3-17 months), and then therapy was restarted. CONCLUSION: This study provides evidence that NB-UVB might be an efficient option for stage IA and IB MF patients.


Assuntos
Micose Fungoide/patologia , Micose Fungoide/radioterapia , Terapia Ultravioleta/métodos , Idoso , Biópsia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fatores de Tempo
3.
J Eur Acad Dermatol Venereol ; 21(3): 384-7, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17309464

RESUMO

BACKGROUND: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is a tyrosine kinase inhibitor that targets those proteins involved in BCR-ABL signal transduction in CML, c-kit (KIT) and platelet-derived growth-factor (PDGFR) receptor. The use of IM has been associated with cutaneous reactions. In the last 2 years numerous studies have focused the attention on hypopigmentations, depigmentations and photosensitivity developing after the initiation of IM therapy. OBJECTIVE: The aim of this study is to evaluate the effects of IM therapy on the skin pigmentation of five patients affected by CML. METHODS: Skin pigmentation measurements were performed with a Minolta CR-200 Chromameter. results: All the studied patients show the gradual lightening of the skin on unexposed areas over the treatment with IM. In particular, this explorative colorimetric study indicates the association between IM and skin depigmentation with a significant increase of luminance value (L*) (P = 0.001) and a significant decrease of the pigmentation value (b*) (P = 0.028). CONCLUSION: Even if we do not know the clinical significance of the skin depigmentation caused by IM, the regulatory role of KIT and its ligand stem cell factor in melanocyte development and survival seems to suggest an objective mechanism of action for IM in the pathogenesis of this cutaneous depigmentation.


Assuntos
Antineoplásicos/uso terapêutico , Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico , Piperazinas/uso terapêutico , Pirimidinas/uso terapêutico , Pigmentação da Pele/efeitos dos fármacos , Adolescente , Adulto , Idoso , Benzamidas , Colorimetria , Feminino , Humanos , Mesilato de Imatinib , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Estatísticas não Paramétricas
4.
Photodermatol Photoimmunol Photomed ; 22(4): 211-3, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16869872

RESUMO

The treatment of vitiligo is still a challenge. Among various therapeutic modalities, phototherapy with UVB narrowband (UVB-NB) is presently considered a treatment of choice for this skin disease. The exact skin cancer risk deriving from UVB-NB is a serious concern to be determined. We report a case of keratoacanthoma developed in the vitiligo area during a prolonged course of UVB-NB therapy.


Assuntos
Ceratoacantoma/radioterapia , Terapia Ultravioleta/efeitos adversos , Vitiligo/radioterapia , Idade de Início , Seguimentos , Humanos , Ceratoacantoma/diagnóstico , Ceratoacantoma/patologia , Masculino , Pessoa de Meia-Idade , Fatores de Tempo , Resultado do Tratamento , Terapia Ultravioleta/métodos , Vitiligo/patologia , Vitiligo/cirurgia
5.
Int J Immunopathol Pharmacol ; 18(4): 755-60, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16388725

RESUMO

Photochemotherapy with psoralen plus ultraviolet A(PUVA) and phototherapy with UVB narrow band (UVB-NB) are used in the treatment of psoriasis. Numerous studies have shown that the additional administration of either topical or systemic antipsoriatic agents may effectively increase the efficacy of these therapies. This study aimed to compare through objective data the efficacy of topical tacalcitol in combination with PUVA or UVB-NB versus PUVA and UVB-NB monotherapy in the treatment of mild to moderate chronic plaque psoriasis. Modified Psoriasis Area and Severity Index (PASI) score, transepidermal water loss (TEWL) and stratum corneum hydration were used to monitor the restoration of skin barrier in the psoriatic plaques of 40 patients during photochemotherapy. The study was a right-left, intra-individual, pre/post comparison trial. PUVAand UVB-NB treatments were given three times a week. On those plaques localized on the right side of the body tacalcitol ointment was applied once a day, in the evening. Corneometry, TEWL and modified PASI score were used to evaluate the response to the treatment at baseline, one month and two months. Thirty-six of the forty enrolled subjects completed the study. The comparison between combination treatments and the PUVA/UVB-NB monotherapy showed no significant differences with regard to modified PASI index. However, significant differences were recorded with regard to TEWL and corneometry. The combination of tacalcitol plus PUVA or tacalcitol plus UVB-NB restored epidermal barrier functions as well as skin hydration faster than PUVA or UVB-NB monotherapy (TEWL: p=0.0050 and corneometry: p=0.003). The combination of tacalcitol plus UVB-NB allowed a better restoration of skin barrier functions than tacalcitol plus PUVA (p=0.013). In conclusion, the combination of tacalcitol plus PUVA or plus UVB-NB improves the therapeutic result. In addition, the data from TEWL and skin hydration suggest a means in which tacalcitol plus UVB-NB induces a better normalization of skin biophysical parameters.


Assuntos
Fármacos Dermatológicos/uso terapêutico , Di-Hidroxicolecalciferóis/uso terapêutico , Ficusina/uso terapêutico , Terapia PUVA , Fármacos Fotossensibilizantes/uso terapêutico , Psoríase/terapia , Adolescente , Adulto , Idoso , Fármacos Dermatológicos/administração & dosagem , Di-Hidroxicolecalciferóis/administração & dosagem , Feminino , Ficusina/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Pomadas , Fármacos Fotossensibilizantes/administração & dosagem , Psoríase/tratamento farmacológico , Psoríase/radioterapia , Pele/química , Pele/patologia , Água/química , Perda Insensível de Água
6.
J Eur Acad Dermatol Venereol ; 18(4): 467-70, 2004 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15196164

RESUMO

Eosinophilic pustular folliculitis (EPF) is an unusual disease, first described in adult East Asians in 1970 by Ofuji. It is characterized by follicular papules and pustules tending to coalesce and form plaques involving the trunk, face and extremities. In recent years, it has been often associated with human immunodeficiency virus (HIV) infection or with immunosuppressed and/or oncohaematological patients. EPF has been described in immunocompetent adult caucasian patients only occasionally. The diagnosis requires clinical and microbiological features such as sterile folliculitis and histopathological findings characterized by folliculitis and perifolliculitis with eosinophilic infiltrate. We describe an HIV seronegative caucasian male with EPF, allergic to non-steroidal anti-inflammatory drugs and indomethacin, treated with oral doxicycline. The treatment led to the complete remission of the lesions within 2 months.


Assuntos
Antibacterianos/uso terapêutico , Doxiciclina/uso terapêutico , Eosinofilia/tratamento farmacológico , Dermatoses Faciais/tratamento farmacológico , Foliculite/tratamento farmacológico , Eosinofilia/patologia , Dermatoses Faciais/patologia , Foliculite/patologia , Soronegatividade para HIV , Humanos , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...